Tau
is a neuronal protein linked to pathologies called tauopathies,
including Alzheimer’s disease. In Alzheimer’s disease,
tau aggregates into filaments, leading to the observation of intraneuronal
fibrillary tangles. Molecular mechanisms resulting in tau aggregation
and in tau pathology spreading through the brain regions are still
not fully understood. New tools are thus needed to decipher tau pathways
involved in the diseases. In this context, a family of novel single
domain antibody fragments, or VHHs, directed against tau were generated
and characterized. Among the selected VHHs obtained from screening
of a synthetic library, a family of six VHHs shared the same CDR3
recognition loop and recognized the same epitope, located in the C-terminal
domain of tau. Affinity parameters characterizing the tau/VHHs interaction
were next evaluated using surface plasmon resonance spectroscopy.
The equilibrium constants KD were in the
micromolar range, but despite conservation of the CDR3 loop sequence,
a range of affinities was observed for this VHH family. One of these
VHHs, named F8-2, was additionally shown to bind tau upon expression
in a neuronal cell line model. Optimization of VHH F8-2 by yeast two-hybrid
allowed the generation of an optimized VHH family characterized by
lower KD than that of the F8-2 wild-type
counterpart, and recognizing the same epitope. The optimized VHHs
can also be used as antibodies for detecting tau in transgenic mice
brain tissues. These results validate the use of these VHHs for in
vitro studies, but also their potential for in-cell expression and
assays in mouse models, to explore the mechanisms underlying tau physiopathology